This brand name is authorized in Estonia, Lithuania, Turkey
The drug DAUNOSIN contains one active pharmaceutical ingredient (API):
|
1
Daunorubicin
UNII UD984I04LZ - DAUNORUBICIN HYDROCHLORIDE
|
|
Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. Daunorubicin may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01DB02 | Daunorubicin | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1799376 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1090584 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699828790389 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
